HYPERFINE Stock Price, News & Analysis

Hyperfine, Inc. (Nasdaq: HYPR) announced groundbreaking data on its Swoop® portable MRI system at the 2023 International Stroke Conference. The study, conducted at Yale-New Haven Hospital, focused on stroke patient follow-ups using bedside portable magnetic resonance imaging following mechanical thrombectomy procedures. The findings suggest that low-field pMRI can assess ongoing brain injury that is typically unmonitored due to the unavailability of conventional imaging post-procedure. Hyperfine's CEO highlighted the significance of these advancements in improving patient care and diagnostics.

Hyperfine, Inc. (Nasdaq: HYPR) announced the appointment of Brett Hale as Chief Administrative Officer and Chief Financial Officer, effective February 13, 2023. Hale brings over 25 years of experience in finance, predominantly in the medical technology sector, having held CFO positions at various companies, including Bigfoot Biomedical. He succeeds Alok Gupta, who will transition out by March 31, 2023. The transition is expected to enhance Hyperfine's operational efficiencies and expand the adoption of its portable MRI system, Swoop. In connection with his hiring, Hale was granted inducement stock options to purchase 1 million shares, vesting over four years.

Hyperfine, creator of the Swoop® Point-of-Care MRI System™, recently announced the acceptance of twelve abstracts for presentation at the ISMRM and ISMRT annual meeting in Toronto from June 3–8, 2023. The research, conducted by teams from prestigious institutions like UPenn and NYU, includes advanced topics in MRI technology. The Swoop® system aims to enhance patient outcomes by providing portable, ultra-low-field brain imaging at the bedside. The ongoing research supports Hyperfine's mission to revolutionize patient care through accessible MRI technology.

Hyperfine (Nasdaq: HYPR), a leader in medical technology, announced its participation in the 5th Annual Evercore ISI HealthCONx Conference scheduled for November 30, 2022, at 9:15 AM Eastern Time. The company will present their groundbreaking Swoop®, the world’s first FDA-cleared portable MRI system, which enhances patient access to MRI diagnostics.

Interested individuals can view the live and archived webcast via the Investors section of their website.

Hyperfine, Inc. (Nasdaq: HYPR) reported Q3 2022 revenues of $2.348 million, up from $0.371 million year-over-year. The net loss improved to $13.171 million, or $0.19 per share, compared to a loss of $16.392 million, or $8.66 per share in Q3 2021. The company installed 10 Swoop systems in the quarter, totaling 30 installations for the year. Management expects full-year revenue between $7 million and $8 million and anticipates 35 to 45 commercial units installed in 2022, reflecting ongoing growth despite net losses.

Hyperfine, Inc. (Nasdaq: HYPR) announced it will release its third-quarter 2022 financial results on November 10, 2022. Following the release, management will conduct a conference call at 1:30 PM PT / 4:30 PM ET. Interested participants can register online to listen. Hyperfine is known for its innovative Swoop® system, the first portable MRI device cleared by the FDA, which allows for quick diagnostics and treatments in various healthcare settings, improving patient access to essential imaging services.

Hyperfine, Inc. (Nasdaq: HYPR) announced Maria Sainz as its new President and CEO, effective October 24, 2022. Sainz, with over 30 years of experience in the medical device sector, has previously led multiple companies and has been a board member since Hyperfine's Nasdaq listing. She aims to expand the adoption of Hyperfine's portable MRI system, Swoop, which is already installed in over 90 locations globally. The company seeks to enhance medical imaging access worldwide while maintaining a disciplined spending approach to drive growth.

Hyperfine (Nasdaq: HYPR) announced management's participation in two upcoming conferences. Scott Huennekens and Alok Gupta will present at the Gilmartin Group Emerging Growth Company Showcase on August 31, 2022, at 1:00 PM EDT. A live webcast will be available. Gupta and Khan Siddiqui will present at the 2022 Wells Fargo Healthcare Conference on September 8, 2022, at 9:10 AM EDT, with a live and archived version accessible online. Hyperfine is known for Swoop, the first FDA-cleared portable MRI system, enhancing patient access to diagnostic imaging.

Hyperfine, Inc. (Nasdaq: HYPR) reported Q2 2022 revenues of $1.533 million, up from $0.358 million in Q2 2021, reflecting strong adoption of its portable MRI system, Swoop. However, the company faced a net loss of $23.159 million, compared to a loss of $14.580 million in the same period last year. Hyperfine installed 9 new systems, bringing total installations to 47. The company anticipates 2022 revenues of $7 million to $8 million and plans to install 35 to 45 commercial units. Positive developments include FDA clearances for system enhancements and a partnership with Viz.ai for improved patient care.